(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 July 2014 (17.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/110248 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 31/5513* (2006.01)

(21) International Application Number:
PCT/US2014/010863

(22) International Filing Date:
9 January 2014 (09.01.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/750,792 9 January 2013 (09.01.2013) US
61/762,836 8 February 2013 (08.02.2013) US

(71) Applicant: **EDGEMONT PHARMACEUTICALS LLC** [US/US]; 1250 Capital of Texas Hwy, South Building 3, Suite 400, Austin, Texas 78746 (US).

(72) Inventors: **SALTEL, Douglas A.**; c/o Edgemont Pharmaceuticals, 1250 Capital of Texas Hwy, South Building 3, Suite 400, Austin, Texas 78746 (US). **VACHON, Michael**; c/o Edgemont Pharmaceuticals, 1250 Capital of Texas Hwy, South Building 3, Suite 400, Austin, Texas 78746 (US).

(74) Agent: **MUNCY, Joe McKinney**; Muncy, Geissler, Olds & Lowe, P.C., 4000 Legato Rd., Suite 310, Fairfax, Virginia 22033 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: CONTROLLED RELEASE FORMULATIONS OF LORAZEPAM




FIG.1

(57) Abstract: Controlled release of lorazepam can provide enhanced dosing options including once daily dosing that provides 24 hour therapeutic effect under steady state conditions. The pharmaceutical composition can provide substantially zero order release and 90% release within 7 to 12 hours in a pharmaceutical dissolution test. The release can be achieved using polyethylene oxide as a matrix polymer.

WO 2014/110248 A1